Introduzca una acción o criptomoneda en el cuadro de búsqueda para obtener un resumen
Medivir AB
MVIRMedivir AB (publ), a pharmaceutical company, focuses on the development and commercialization of treatments for cancer in Nordic region, rest of Europe, and internationally. The company markets Xerclear for the treatment of labial herpes under the Zoviduo name. It is also developing Remetinostat for treating MF cutaneous T-cell lymphoma and basal cell carcinoma, as well as squamous cell carcinoma. In addition, the company is developing MIV-818 for the treatment of liver cancer; MIV-711 to treat osteoarthritis; and Birinapant and IGM-8444 for the treatment of solid tumors, as well as USP-1/TNG348, USP-7, and MBLI/MET-X, which completed preclinical trials for treating cancer and infection. It has a clinical trial collaboration and supply agreement with Eisai to evaluate fostrox, a liver-targeted treatment, in combination with lenvatinib for the treatment of liver cancer. The company was incorporated in 1987 and is based in Huddinge, Sweden. Address: Lunastigen 5, Huddinge, Sweden
Analytics
Precio Objetivo de WallStreet
266.7 SEKRelación P/E
–Rentabilidad por dividendo
–Año en curso
Año anterior
Trimestre actual
Último trimestre
Año en curso
Año anterior
Trimestre actual
Último trimestre
Cifras clave MVIR
Análisis de dividendos MVIR
Aumento del dividendo durante 5 años
–Crecimiento continuo
–Ratio de pago medio en 5 años
–Tendencia del payout MVIR
Valoración de la acción MVIR
Finanzas MVIR
Realice un seguimiento de las métricas clave de cada acción en un solo lugar y sin complicaciones
Hazte premiumResultados | 2019 | Dinámica |